Open an account

Edwards Lifesciences

EW · NYSE

$88.29+$1.07 (+1.23%)TodayMarket closed ·
Prev close $87.22

About EW

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 16,000 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

Employees
16,000
Headquarters
Irvine, California
Listed
Mar 27, 2000
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
edwards.com

EW key statistics

Market cap
50.89B
Price-earnings ratio
50.13
Dividend yield
—
Average volume
3.74M
Volume
1.80M
Open price
$87.73
High today
$88.34
Low today
$87.16
52 Week high
$96.29
52 Week low
$74.43

Edwards Lifesciences (EW) at a glance

As of Oct 20, 2026, Edwards Lifesciences (EW) shares are priced at $88.29, giving the company a market cap of 50.89B and a price-to-earnings ratio of 50.13.

Today the stock has traded between $87.16 and $88.34. The current price is 1.3% above the day's low and 0.1% below its high.

Volume so far is 1.80M shares, below the average of 3.74M shares a day.

Over the past year Edwards Lifesciences has ranged from $74.43 to $96.29, and now sits 63% of the way up that range.

Edwards Lifesciences met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.78 per share against an estimate of $0.7627.

The average analyst price target is $101.84, 15.3% above the current price, from 21 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

76%of 21 analyst ratings say Buy
  • Buy76.2%
  • Hold23.8%
  • Sell0.0%
Price target · 32 analystsAvg $101.84
Low
$85.85
Now
$88.29
High
$115.50

EW earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 4.2% on average.

  1. Q3 FY24: reported $0.67 per share against an estimate of $0.6597
  2. Q4 FY24: reported $0.59 per share against an estimate of $0.5706
  3. Q1 FY25: reported $0.64 per share against an estimate of $0.6147
  4. Q2 FY25: reported $0.67 per share against an estimate of $0.6418
  5. Q3 FY25: reported $0.67 per share against an estimate of $0.6112
  6. Q4 FY25: reported $0.58 per share against an estimate of $0.6363
  7. Q1 FY26: reported $0.78 per share against an estimate of $0.7488
  8. Q2 FY26: reported $0.78 per share against an estimate of $0.7627

EW news

  • Vandana Singh

    FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death

  • Press releaseBusiness Wire

    Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026

  • Press releaseBusiness Wire

    Edwards Lifesciences to Host Investor Event in Conjunction With TCT

  • Vandana Singh

    Edwards Lifesciences Secures FDA Approval for First Expandable Pediatric Heart Valve

  • Press releaseBusiness Wire

    Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients

  • Press releaseBusiness Wire

    Edwards Lifesciences Comments on TAVR National Coverage Decision

  • Press releasePRNewswire

    Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders?

  • Press releaseBusiness Wire

    Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit

Similar companies

Companies in the same industry as Edwards Lifesciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.